Key result
Combined administration of trandolapril and LU 135252 in rats with chronic heart failure decreased LV systolic and end-diastolic pressures by 32% and 80% but did not additionally improve survival.
Why the study?
Does the combination of an endothelin-A receptor antagonist and an ACE inhibitor improve hemodynamics and survival in a rat model of chronic heart failure?
Does the combination of an endothelin-A receptor antagonist and an ACE inhibitor improve hemodynamics and survival in a rat model of chronic heart failure?
In a rat model of heart failure, combining an endothelin-A antagonist with an ACE inhibitor improves hemodynamics more than either drug alone but does not further improve long-term survival.
Answers are grounded in this paper and cite their sources.
Combination improves hemodynamics without added survival benefit in rat HF; hypothesis-generating and should not yet change practice.
BACKGROUND: In patients with congestive heart failure (CHF) receiving ACE inhibitors, acute administration of selective endothelin (ET) antagonists additionally improves systemic and cardiac hemodynamics. We investigated, in a rat model of CHF, whether such acute synergistic effects are sustained and accompanied, in the long term, by an additional limitation of left ventricular remodeling or an increase in survival. METHODS AND RESULTS: Rats were subjected to coronary artery ligation and treated for 3 or 9 months with vehicle or with the ACE inhibitor trandolapril (Tr) (0.3 mg/kg(-1) per day(-1)), the ET(A) antagonist LU 135252 (LU, 30 mg/kg(-1) per day(-1)), or their combination starting 7 days after ligation. After 3 months, the combination decreased LV systolic- and end-diastolic pressures (-32% and -80%, respectively) more markedly than Tr (-21% and -61%, respectively) or LU alone (-14% and -48%, respectively). Echocardiographic studies revealed that all treatments limited LV dilatation and increased LV fractional shortening and cardiac index. All treatments equally reduced left ventricular collagen density, whereas only Tr or the combination reduced LV weight. Finally, although LU did not modify long-term survival, Tr and the combination of Tr with LU induced a similar improvement of survival. CONCLUSIONS: In this rat model, long-term combined administration of an ET(A) antagonist and an ACE inhibitor induces additional effects in terms of systemic and cardiac hemodynamics; however, this is not associated with an additional increase in long-term survival.
No takes yet. Share an insight, caveat, or question.
Mulder et al. (2002) studied Chronic Heart Failure. Trandolapril and LU 135252 combination vs. Vehicle, trandolapril alone, or LU 135252 alone was evaluated on LV systolic and end-diastolic pressures and long-term survival. Combined administration of trandolapril and LU 135252 in rats with chronic heart failure decreased LV systolic and end-diastolic pressures by 32% and 80% but did not additionally improve survival.
Synapse has enriched 10 related papers. Consider them for comparative context: